According to the Centers for Disease Control and Prevention (CDC), approximately 20 million Americans are infected with HPV. New cases appear at the rate of 6.2 million per year.
Eighty percent of women will acquire sexually transmitted HPV by age 50. Nonetheless, only 20% to 40% of women are currently being screened for HPV using DNA tests in conjunction with a standard Pap smear.
In 2012, the US Preventative Task Force (USPTF) approved the HPV test as a mandatory part of the cervical cancer screening guidelines. The trend toward greater use of HPV testing also continues to grow as data accumulate showing that awareness of infection – as well as the type of infection – is important in preventing continued spread of the disease.
The Trovagene HPV High Risk test can address key barriers to universal screening: cost, convenience, and personal or cultural resistance to traditional testing methods.